The Importance of Proximity to Death in Modelling Community Medication Expenditures for Older People: Evidence from New Zealand by Moore, Patrick et al.
 
 
The Importance of Proximity to Death in Modelling
Community Medication Expenditures for Older
People: Evidence from New Zealand
Moore, Patrick; Bennett, Kathleen; Normand, Charles
DOI:
10.1007/s40258-014-0121-x
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Moore, P, Bennett, K & Normand, C 2014, 'The Importance of Proximity to Death in Modelling Community
Medication Expenditures for Older People: Evidence from New Zealand', Applied Health Economics and Health
Policy, vol. 12, no. 6, pp. 623-633. https://doi.org/10.1007/s40258-014-0121-x
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This is a post-peer-review, pre-copyedit version of an article published in Applied Health Economics and Health Policy. The final
authenticated version is available online at: http://dx.doi.org/10.1007/s40258-014-0121-x
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
1 
 
THE IMPORTANCE OF PROXIMITY TO DEATH IN MODELLING COMMUNITY 
MEDICATION EXPENDITURES FOR OLDER PEOPLE: EVIDENCE FROM NEW 
ZEALAND 
(PROXIMITY TO DEATH AND COMMUNITY MEDICATION EXPENDITURES) 
Patrick V Moorea, Kathleen Bennettb and Charles Normanda 
aCentre for Health Policy and Management, Trinity College Dublin, Ireland  
bDepartment of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St 
James Hospital, Dublin 8, Ireland 
All correspondence to: Patrick Moore, Health Policy and Management, Trinity College Dublin, 3/4 
Foster Place, College Green, Dublin 2, Ireland, Tel: +353 1 8962 672, Fax: +353 1 6774 956, Email: 
moorepv@tcd.ie 
Abstract 
Background 
Concerns about the long term sustainability of health care expenditures and in particular prescribing 
expenditures has become an important policy issue in most developed countries. Previous studies 
suggest that proximity to death (PTD) has a significant effect on total health care expenditures, with 
its exclusion leading to an overestimation of likely growth. There are limited studies of 
pharmaceutical expenditures taking PTD into account.  
Objective 
This paper presents an empirical analysis of public medication expenditure on older individuals in 
New Zealand (NZ). The aim of the study is to examine the individual effects of age and proximity to 
death (PTD) using individual level data.  
Methods 
This study uses individual level dispensing data from 2008/2009 covering the whole population of 
medication users age 70 years or more and resident in New Zealand. A case control methodology is 
used to examine individual cost and medication use for a 12 month period for decedents (cases) and 
survivors (controls). A random effects two part model, with a Probit and Generalized Linear Model 
(GLM) is used to explore the effect of age and proximity to death on expenditures.  
Results 
The impact of proximity to death on prescription expenditure is not as dramatic as studies reporting 
on Acute and/or long term care. The 12 month decedent to survivor mean expenditure ratio was 1.95, 
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2.09 for males and 1.82 for females. The additional cost of dying in terms of prescription drugs 
decreases with age, with those who die at 90 years of age or older consuming fewer drugs on average 
and having a lower mean expenditure than those who died in their 70s and 80s. The following 
variables were found to have a decreasing effect on the mean monthly prescription expenditures, a 
reduction of 2.2% for each additional year of age, 4.2% being in the Mãori ethnic group and 7.8% for 
Pacific Islanders. Increases in monthly expenditure were associated with being a decedent 32.1%-
62.6% (depending on month), being of Asian origin 16.2% or a male 12.6%.  
Conclusions 
Given the variance reported between survivors and decedents, to improve accuracy future projections 
should include PTD in their models. Policies targeted at reducing expenditures should not focus on 
age but on ensuring appropriate and cost effective prescribing especially towards the end of life. 
 
Key points for decision makers: 
 Despite prescription medications being the most common medical intervention there is 
limited evidence on how proximity to death and ageing affect prescribing expenditures for 
older people. 
 In terms of expenditure on prescription medications, proximity to death would appear to be a 
more important driver than ageing and should therefore be considered in any future 
expenditure projections. 
 
1 Introduction and background  
Concerns about the long term sustainability of increasing healthcare expenditure has become 
an important policy issue in most developed countries. Such growth is increasing pressure on 
government budgets, healthcare providers and individuals. Understanding drivers of this 
growth should enable us to more accurately forecast future expenditures and inform 
appropriate policies. The New Zealand population over 65 years of age is predicted to more 
than double in the next two decades similar to the majority of other developed countries [1, 
2]. In addition, the working population (15-64) will only increase marginally increase [1, 2] 
or even decline [2] leading to an increase in the old age dependency ratio of those aged 70 
years or more to those aged 15-64 years [3, 2]. As a result of this demographic shift a reduced 
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proportion of the population will be supporting an increased older population. Policy makers 
in New Zealand and other developed countries with similar ageing populations are concerned 
about a significant health care cost increase associated with the anticipated population shift. 
 
Studies frequently associate ageing with higher health care costs relative to the younger 
population [4, 5]. While age may be important to an extent, Fuchs [6] proposed the idea of 
proximity to death (PTD) having an important positive effect on health care costs. The 
premise being the closer someone is to death, the more health care resources they use 
resulting in higher health care expenditure. A higher rate of mortality in older age groups 
could be a confounder in the age expenditure relationship. Several studies have presented 
evidence of increased healthcare expenditures for those close to death [7-11].  Other studies 
have reported that ageing is more important [12], that proximity to death is minor in 
magnitude [12], or indeed a proxy for disability [13]. Van  Baal  and Wong [14] suggest that  
PTD  may  be  a  better   predictor of expenditure than age as it includes both age and 
mortality risk. There remains general consensus on a PTD effect, what is contentious is the 
magnitude.  
All these previous studies have focused on hospital or long term care expenditures with little 
separate analysis of medication expenditures. Public spending on prescription medications is 
a significant commitment, accounting for approximately 18.7% on average of total healthcare 
spending in OECD countries (12% in New Zealand)[15]. Traditional predictions of future 
expenditure using prescription drugs have not taken into account the effect of proximity to 
death (PTD) on individual expenditures [16]. One Danish study has examined medication 
expenditure and reported that the effect of ageing on future drug expenditures will be 
overestimated when not accounting for proximity to death [17]. Given the rising volume and 
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costs of prescribing experienced in developed countries [18], gaining an understanding of 
what effects health care expenditure in this area will help policy makers to more accurately 
predict and develop new policies to control future spending on prescription drugs. The aim of 
this study is to examine the association between age, proximity to death and medication 
expenditure by examining the expenditures of decedents and survivors.   
2 Data and Methods 
Prescribing and mortality data for individuals 70 years of age and older were extracted from 
the New Zealand Ministry of Health Pharmacy Claims Data warehouse for 2007-2010. Each 
prescription record contains a unique person identifier, date of birth, ethnic group, gender, 
age, date of dispensing and ingredient cost. Ingredient cost is the amount of New Zealand 
dollars the state has paid the pharmacist for the medication at 2008/2009 prices and does not 
include dispensing fees or co-payments made by individuals. Mortality records include a 
unique person identifier, the date of death, age at death and place of death. Unlike previous 
studies examining Health Care Expenditure (HCE) which used samples, this study uses a 
national cohort.  
The prescribing and mortality records were merged using an anonymised version of the 
unique health identifier (National health index NHI) to create one dataset including survivors 
from 2008/2009 who lived beyond 2009 and those who died in 2009 (decedents). Prescribing 
data are over two years, 2008-2009 in order to gain a full 12 months of observations for 
decedents. Survivors are those who were not in their last year of life in 2008. Mortality data 
was used from 2009 to identify decedents and to ensure survivors are not in their last year of 
life.  
5 
 
In order to gain an insight into the differences between decedents and non-decedents 
(survivors) a matched case-control study methodology was used.  The mortality dataset was 
utilized to identify decedents in 2009 as cases, and match them 1:1 based on age, gender and 
ethnic group to controls (survivors) from 2008. Data for survivors was calculated for the year 
January to December 2008. Coarsened exact matching (CEM) was used, this involved three 
steps: First the matching variables were coarsened into broader groups (similar to creating a 
histogram by putting the variables into categories or bins) e.g. Age into 5 year bands; 
Secondly data were exactly matched using the matching variables, which involves sorting the 
observations into strata, each with unique values of the matching variables; Thirdly Strata 
containing only control units were discarded; strata with case and control units were retained. 
A detailed description of CEM and its merits over other matching methods is given by Iacus 
et al [19]. The total population over 70 years of age considered in the study can be broken 
down into three groups as shown in Figure 1. A total number of 20,161 decedents or cases 
matched to 20,161 survivors or controls with only 3 cases not matched, this was due to the 
very small numbers of older people in certain ethnic groups.  
2.1 Econometric specification 
Exploratory data analysis was conducted followed by an econometric data analysis which 
included: two part model (TPM) was estimated using a Probit and GLM; TPM was tested for 
cross-sectional dependence; TPM was tested for suitability for panel data framework 
(Likelihood ratio test and F-test). 
Monthly expenditure on prescription medicines has a spike at zero and for those individuals 
who do incur expenditure the distribution is right skewed with non-constant variance. This 
distribution is typical of health care cost data therefore any regression methods must take 
account of the skewed data and focus on the population means [20, 21].  If an Ordinary Least 
Squares (OLS) regression methodology was used with a log transformation to account for the 
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skewness the analysis would not be based on the population means but rather the mean on the 
log scale. This scale would measure geometric means and require a system of back 
transformation for interpretation [22-24, 21].  
In the study population of 4.2 million monthly expenditure observations 1.6 million (38.7%) 
have a zero value. The total monthly cost variable is heavily skewed (kurtosis=2,371, 
skewness=35) and has considerable non-normal kurtosis, if zero values are ignored the 
skewness is only slightly reduced while kurtosis shows a relatively larger reduction 
(kurtosis=1,651, skewness=30)
1
. After careful consideration of the data using a modelling 
strategy the best fitting was a two part model with a Probit model to first identify the 
likelihood of monthly expenditure by modelling a dictonomous dependent variable for 
whether or not there was an expenditure in a given month and then a generalized linear model 
(GLM) was run conditional on the presence of non-zero prescribing expenditure to estimate 
the monthly medication expenditure of individuals. The two part model assumes that the zero 
values and the positive values are generated by different independent mechanisms. Duan et al 
[25] and Jones [26] provide more in-depth discussion of the merits of the two part model. 
Given the nature of the panel dataset, a large number of observations over a short 12 month 
period, we have not concerned ourselves with testing for stationarity. Two tests were 
conducted to ascertain if panel data methods were appropriate for the two part model as 
follows. A likelihood ratio test was conducted on the first part of the model to test for panel-
level variance equal to zero and concluded that there was no evidence of zero variance. An F-
test was conducted on the second part of the model to test if all individual specific effects 
were equal to zero, this hypothesis was rejected. The following Probit model was run to 
examine the effects of age, gender, proximity to death and ethnic group on the probability of 
using medication in a given month.  
                                                 
1
 Normal values: Kurtosis=3, skewness=0. 
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Where A: individual age; G: Male gender; D: decedent; M: months until death or censor; E: 
Ethnic group; MD: decedent-month interaction term 
The second part of the model is a random effects GLM which facilitates the analysis of mean 
costs while allowing for the non-normal distribution of the data. A major advantage of the 
GLM is that it models the mean and link (variance) functions on the original scale of cost. 
The model consists of a distribution function for costs and a link function which describes the 
scale of the relationship of the covariates with the cost. The various GLMs were assessed 
using the modified Parks test following Manning and Mullahy [21], Akaike Information 
Criteria (AIC) [27] and normal probability plots of deviance residuals to ascertain a suitable 
distribution function. While there is no one test for assessing an appropriate link function the 
following three tests were run for guidance: Pearson correlation test; Pregibon link test; a 
modified Hosmer and Lemeshow test.  The consistent result from these tests was an inverse 
gaussian distribution function and a log link.  
                                        
  
   
      
 
   
      
  
   
   
 
The use of a log link function in the GLM means the coefficients act multiplicatively on the 
mean, by taking the exponential they can be expressed as the percentage increase in the mean 
monthly medication expenditure per unit increase in the covariate [28]. A random effects 
model is more appropriate for the dataset over a fixed effects model for a number of reasons, 
principally the loss of coefficients for time-invariant variables such as gender and ethnic 
group and the exclusion of individuals with all zero or all positive monthly expenditures. A 
Breusch-Pagan LM will test for the appropriateness of a random effect model. 
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The original 26 codes for ethnic groups (see Appendix) were condensed into six, starting with 
the largest: European, not stated, Mãori, Asian, Pacific Islands and other. Age was split into 
four five year bands and a 90+ category for exploratory analysis and maintained as a 
continuous variable for regression analysis. The number of items variable is a count of 
medicines dispensed in each month, it has a monthly median of 2, a monthly mean of 4 (std 
dev. 7.12) and a range of 0 to 460. 
3 Results 
3.1 Descriptive statistics 
Table I outlines in more detail the three characteristics - gender, age and ethnic group - that 
were used to match the decedents (case group) to survivors (control group).  Separating the 
population into survivors and decedents shows the difference in number of items used and 
ingredient costs of those in their last 12 months of life. Figure 2 shows the mean 12 month 
expenditure by age group for male and female decedents and survivors. The mean costs for 
decedents decreases with age, from NZ$2,259 in the 70-75 age group to NZ$864 in the 100+ 
group, a 62% decrease in cost. The mean cost for survivors increases to a peak of NZ$933 in 
the 85-89 age group and decreases thereafter. Figure 3 plots the mean number of items used 
in the 12 month period. The patterns in Figures 2 and 3 show that while mean expenditure for 
decedents decreases with age group, mean items dispensed peaks in the 80-84 age group and 
declines thereafter. This would suggest that older decedents use more and less expensive 
items on average than younger decedents. In contrast the mean cost of survivors increases 
with age in line with the number of items, but again there is a change in the 85+ age groups 
where the cost remains level but the number of items continues to increase. While at every 
age decedents use more items and have a higher mean expenditure than survivors, the 
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additional “cost of dying” decreases with age as demonstrated in Figure 4 which shows the 
decedent / survivor ratio narrowing as age group increases.  
 
Results given in table II show the matching of the case group of decedents taken from 2009 
and followed back to 2008 with a matched control group from 2008. The mean expenditure 
ratio (decedents/ survivors) in table II shows that decedents are on average 1.95 times more 
costly than survivors, which ranges from 2.09 for males to 1.82 for females. This ratio 
declines with age as seen in Figure 4. The all age mean cost per item is similar for both 
groups while the number of items per individual is 1.95 times more for decedents. 
 
3.2 Medication use 
A comparison of the medications dispensed to decedents in the 12
th
 month from death and in 
the last month before death shows, as expected, a significant increase in medications over the 
12 month period.  In the last month of life over double the number of items were dispensed to 
the decedents in comparison to the matched survivors. In the last month of life there is a 
significant increase in use across most therapeutic groups compared to the 12
th
 month. The 
largest being the Nervous System (N)
2
 with an overall 3.8 times rise driven by large absolute 
increases in analgesics (N02) (4.6 times), anti-nausea & vertigo agents (N07C and A04) (12.9 
times), antipsychotic (N05A) (5.4 times), sedative (N05C) (3.2 times), anti-epilepsy (N03) (4 
times) and antidepressant (N06A) (4 times) medications. While medication use increases on 
average in the last month before death it does not show a dramatic rise or pattern in the 
preceding months.  
3.3Regression analysis 
                                                 
2
 Medications are reported using the WHO Anatomical Therapeutic Chemical (ATC) system 
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A Breusch-Pagan LM test rejected a null hypothesis of variances across individuals being 
zero, this would suggest that a random effects model, which takes account of the panel effect, 
is more appropriate than using an Ordinary Least Squares (OLS) method. Table III sets out 
the results of a two part model, with the Probit showing the probability of expenditure on 
prescription medication and the GLM regression the effect on monthly expenditure per 
individual with the listed explanatory variables.  The reference groups being female, of 
European ethnicity and the 12
th
 month before death or censor. An interaction term with 
decedent was included for each month and all were found to be significant.   
An increase in one year of age has a decreasing effect on mean monthly costs, 2.2% on 
average, adjusting for the contributions of the other explanatory variables. Decedents have a 
higher monthly expenditure in every month leading up to death. In terms of ethnic groups, 
those of Asian origin had considerably higher monthly expenditures, while Mãori and Pacific 
islanders had lower expenditures. Only Mãori had an increased likelihood of medication use, 
as seen in part 1 of the model.  
Part 1 of the model shows that with 12 months prior to death as the baseline there is a 
constant upward trend in the likelihood of medication use in months 11 to 1. The proximity 
effect extends at least 12 months prior to death.  
Monthly expenditures for individuals who are dispensed a medication show no consistent 
increasing trend prior to death other than those who die being consistently 1.3 to 1.4 times 
greater than survivors with a more noted increase in the last month of life to 1.6 times greater. 
Even when the decedent time span is expanded to 24 months there is no convergence or surge 
in use towards the end of life, apart from the last month (data not shown here). But decedents 
do on average use twice as many items as survivors over the whole period, and are more 
likely than survivors to have used medication in any given month.  
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4 Discussion 
This study provides evidence of the importance of accounting for proximity to death rather 
than ageing alone for expenditure on prescription drugs in an older community based 
population. In fact the regression results show that ageing has a negative effect on 
prescription expenditure.  By comparing prescription expenditures for decedents in the last 12 
months of life to a similar group of survivors we can see that decedents cost on average 
between 1.82 and 2.09 times more. Similar to other studies mean HCE per annum is rising 
after 70 years of age with a peak in the 80 to 84 year age group and a decline there after in the 
total population and the survivors control group [29, 11]. The mean number of items used in 
the 12 month period by survivors increases linearly with age but at a greater rate than 
expenditure which suggests that while survivors are using more items in these older groups 
they are relatively cheaper medications. The increases in mean items and cost of survivors 
with age may be due to increasing rates of chronic illness, as the number of people over 70 
years of age reporting one or more chronic illness increases with age [30].  In contrast 
descendants demonstrate a dramatic decrease in expenditure which is combined with a more 
staid increase in mean number of items, this is in line with other HCE studies which have 
reported a decrease in the “cost of dying” with age [31, 32].  
The study adds to the existing literature on proximity to death by providing evidence on 
patterns of prescribing costs. This study reports a similar magnitude for the PTD effect as a 
Danish study [17] which reported a mean cost ratio of 1.7 for those aged 75 years or more. 
The Danish study also reports that ageing will increase future drug expenditures but taking 
PTD into account they conclude that the increase will be relatively small [17]. In contrast a 
Dutch study examining macro level data suggests that accounting for PTD may not simply 
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reduce future projections of HCE due to growth from other unidentified causes which were 
not included in previous modelling attempts [14].  
Similar to a Spanish study [33] we found age to have a positive influence on the probability 
of pharmaceutical expenditure, in contrast the Spanish study additionally found a positive 
association between age and the amount of expenditure but was focused on individual doctors 
prescribing and excluded PTD.  Studies looking at total health care expenditures have 
reported increasing expenditures with age [34, 12] with some attributing it to proximity to 
death [10, 31, 35]. This study has focused on prescribing expenditures and found that they do 
not steadily increase with age for the older population even before accounting for PTD.  
Instead they show a bell curve peaking in the early 80 years of age and declining thereafter. 
The effect of proximity to death on prescription expenditures is less than the PTD effect 
reported in studies looking at total HCE and long term care (LTC) this may in part be due to 
the high uptake of hospital and long term care services at the end of life and the high volume 
of preventative medication in use by survivors.  
The pattern of decreasing cost ratio of decedents to survivors shown in Figure 4 is similar to 
other studies [34, 31]. This suggests that, in terms of medication, the cost of dying relative to 
surviving actually decreases with age. Two other explanatory factors worth considering are 
the numbers of individuals who die in hospitals or long term care facilities in these age 
groups and the fact that those who do remain living in the community are potentially 
healthier.  
The fact that decedents on average have a higher use and expenditure in the 12
th
 month and 
even as far out as the 24
th
 month before death suggests that increased medication use may be 
a sign of a health crisis and subsequent mortality.  
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While this study reports mean expenditure for decedents to be double that of survivors, 
regression models show a smaller increase between the groups for each of the 12 months 
before death. This result does not demonstrate a clear pattern of increasing cost with 
proximity to death but that expenditure for decedents is consistently higher with a peak in the 
last month prior to death. The data suggest that there are other factors driving the higher drug 
expenditures amongst the older population in addition to proximity to death.  More complex 
country specific issues such as the agreements and bargaining power of the public health 
system and patent expiry dates should be considered in addition to PTD. The data 
demonstrate that the proximity of death effect persists beyond the 12 month period studied 
herein. Previous studies have suggested a distance of up to 6 years for the PTD effect [11]. 
A previous study looking at the effect of PTD, age and disability on LTC expenditures 
reported that PTD was acting as a proxy for disability [13] while this current study lacks 
outcome or disability data it is difficult to argue that disability increases prescription 
expenditure more than PTD in community prescribing.   
In terms of differences in expenditures by ethnic minorities, it could be hypothesized that 
Mãori and Pacific Islanders who are in the older age groups are the healthiest of their 
respective groups, based on evidence that suggests members of these ethnic groups are more 
likely to have poorer health and lower life expectancies  [36, 37]. An alternative hypothesis 
for these lower expenditures could be reduced up take of medications or impaired access by 
these ethnic groups [38, 39].  
Life expectancies are increasing in general and evidence suggests that these additional years 
are being lived in good health [40, 41].  In order to use these results to more accurately model 
future data we need to consider increases and convergences in life expectancies. If current 
trends in life expectancy continue the average 70 year old in 2059 will be further from death 
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than a 70 year old in 2008. As proximity to death results in increased prescribing costs in all 
age groups it is important to account for the shift in mortality rates in each age group which 
increasing life expectancies will bring. Converging life expectancies between men and 
woman (woman outlived men by some 3.7 years in 2010 [42]) would mean couples will be 
potentially living longer together which should have a positive effect on health outcomes and 
ultimately a negative effect on health care expenditures.  
The implications of these findings do not just apply to policies to control future expenditures. 
Cost effectiveness analysis relies on future projections which often do not take into account 
PTD leading to an over estimation of the cost effectiveness ratio [43, 44]. 
4.1 Strengths and Limitations 
This study focuses on a key expenditure component of total health care costs, examining the 
services that make up total health care costs is important to fully understand the effect of 
ageing [31].  Some of the studies discussed in this paper used potentially non-representative 
samples such as those taken from private health insurance or hospital datasets. The strength 
of this study lies in its use of population data which is automatically collected by the health 
care system every time a prescription is dispensed, therefore there is no recall or prestige 
biases involved and no sampling issues.  
A limitation of the study is the possible confounding from the large numbers of older people 
who die in hospitals or long term care, with those living in the community at older age 
cohorts the potentially healthier of their age group.  Estimates suggest that New Zealand has a 
higher proportion of its older population in LTC than most OECD countries, with estimates 
of up to 9.2% [45] . Further evidence for this hypothesis is also present in the decline of 
medication use with age in the older groups. Based on previous hospital based studies [31, 
46, 29] which included pharmaceuticals as part of total health care expenditure we would 
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expect the inclusion of such medications to increase the expenditure gap between decedents 
and survivors.   
According to population estimates the over 70 population was 371,950 for 2008 [47], 
therefore the prescribing dataset used in this study is potentially missing 3.5% of the total 
population in this age group. This potential 3.5% would comprise of people over 70 who did 
not die or did not receive any prescription medicines in 2008/2009. In addition the dataset 
lacks information on potential confounders such as medical history for both decedent and 
survivor groups, e.g. diagnoses, severity of any illness, disability, smoking, alcohol etc. The 
study does not contain any information on the use of over the counter (OTC) medicines 
which may or may not have an impact on the cost of public prescribing. It’s likely that the 
future burden of morbidity and patterns of medication use will be altered by new and 
improved preventative and curative treatments which may be developed or price reductions, 
patent expiries and the lifestyle changes of individuals.  
5 Conclusion 
This study primarily investigated the relationship between expenditure on prescription 
medication, proximity to death and age, using a population of 349,174 individuals, 70 years 
of age or more, over a 12 month period. The analysis found that the additional “cost of 
dying” is on average twice that of a similar group of survivors. There is a notable increase in 
decedent prescribing during the last month of life; while all other months are consistently 
higher they do not demonstrate an increasing pattern towards death. Regression analysis 
suggests that while age has a positive influence on the probability of expenditure, it has a 
negative effect on monthly expenditures in line with exploratory analysis which shows lower 
monthly expenditures for the oldest age groups. The results show a positive effect of PTD on 
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prescription expenditure in line with some previous evidence. Compared to studies examining 
long-term care and acute care costs the magnitude of the effect of PTD is considerably lower. 
Given the variance between survivors and decedents future projections should include PTD in 
their models. Policies aimed at reducing expenditures should not focus on age but on 
ensuring appropriate and cost effective prescribing especially towards the end of life. 
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Figure 1 Participant Flowchart 
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Figure 2 Mean expenditure per individual by age group 2008/2009 
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Figure 3 Mean number of items per individual by age group 2008/2009 
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Figure 4 Decedent / survivor cost ratio by age group 
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Table I Characteristics of total population and decedents 
 Characteristic Total 
population 
Decedents 
Gender Male (%)  141,365 (43%) 9,306 (46%) 
 Female (%) 187,632 (57%) 10,855 (54%) 
Age Mean (SD) 76.5 (5.9) 81.9 (7.1) 
 Median (range) 75 (70-111) 82 (70-107) 
Ethnicity European (%) 267,594 (81.3%) 17,503 (86.8%) 
 Mãori (%) 12,673 (3.9%) 1,112 (5.5%) 
 Pacific peoples (%)  5,893 (1.8%) 364 (1.8%) 
 Asian (%) 10,076 (3.1%) 312 (1.6%) 
 Other (%) 880 (0.3%) 30 (0.2%) 
 Not stated (%) 31,894 (9.7%) 843 (4.2%) 
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Table II Ingredient expenditures for 12 months prior to death or censored (1:1 coarsened 
exact matching on age, gender, ethnic group)  
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 Nr of 
individuals 
Total annual 
expenditure 
(standard 
deviation)  
(NZ$) 
Mean 
expenditure 
per individual 
 (standard 
error) 
(NZ$) 
 
Median 
expenditure 
per individual 
(NZ$) 
 
Mean nr of 
items per 
individual 
(95%CI) 
Average 
expenditure 
per 
prescription 
(NZ$) 
Mean 
expenditure 
ratio 
(Decedents 
/Survivors) 
Median 
expenditure 
ratio 
(Decedents 
/Survivors) 
Cases 
 
20,161 20,749,092 
(2,030)   
1,029.17 
(14.30) 
614.41 109 
[108-110] 
9.47 1.95 1.74 
Female 10,855 10,284,171 
(1,973)    
947.41  
(18.94) 
601.11 115 
[113-117] 
8.23 1.82 1.62 
Male 9,306 10,464,921 
(2,091) 
1,124.53 
(21.67) 
633.96 102 
[100-104] 
11.19 2.09 1.89 
Controls 20,161 10,642,978
(928) 
527.90 
(6.54) 
352.45 57 
[56-58] 
9.35   
Female 10,855 5,644,264 
(885) 
519.97 
(8.50) 
370.50 66 
[64-67] 
8.06   
Male 9,306 4,998,714 
(976) 
537.15 
(10.12) 
334.67 47 
[46-49] 
11.48   
28 
 
Table III Probit and Generalized linear model (GLM) of monthly prescribing expenditures 
for decedents assuming an inverse Gaussian distribution with a log link. 
 Part 1 - Probit Part 2 - GLM 
Covariates 
Coefficient  
Standard. 
error 
Coefficient 
Standard. 
error 
age ***0.0470 0.0003 ***0.9783 1.0002 
Male ***-0.2342 0.0039 ***1.1259 1.0027 
Mãori ***0.0481 0.0101 ***0.9576 1.0070 
Pacific Islands ***-0.4024 0.0146 ***0.9220 1.0109 
Asian ***-0.5673 0.0113 ***1.1618 1.0101 
Other ***-0.2762 0.0376 ***1.0949 1.0300 
Not stated ***-0.4657 0.0066 ***0.7838 1.0045 
1 month ***0.2490 0.0037 ***1.0418 1.0066 
2 months ***0.2383 0.0037 ***1.0341 1.0065 
3 months ***0.1077 0.0036 **0.9848 1.0065 
4 months ***0.1402 0.0036 1.0017 1.0066 
5 months 0.1187 0.0036 1.0098 1.0066 
6 months ***0.0097 0.0036 ***0.9754 1.0066 
7 months ***0.0644 0.0036 ***0.9693 1.0065 
8 months ***0.0272 0.0036 ***0.9787 1.0066 
9 months *0.0065 0.0036 ***0.9715 1.0066 
10 months ***-0.0641 0.0036 ***0.9345 1.0066 
11 months 0.0142 0.0036 **0.9836 1.0066 
Decedent*1 month ***0.8849 0.0168 ***1.6260 1.0200 
Decedent* 2 months ***0.8467 0.0167 ***1.3774 1.0185 
Decedent*3months ***0.8269 0.0161 ***1.4068 1.0185 
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Decedent*4 months ***0.7046 0.0158 ***1.3481 1.0184 
Decedent*5months ***0.6400 0.0155 ***1.3205 1.0184 
Decedent*6months ***0.7008 0.0153 ***1.4282 1.0189 
Decedent*7months ***0.5749 0.0150 ***1.4185 1.0188 
Decedent*8 months ***0.5739 0.0149 ***1.3882 1.0188 
Decedent*9months ***0.5478 0.0148 ***1.3856 1.0188 
Decedent*10months ***0.5708 0.0146 ***1.4300 1.0188 
Decedent*11months ***0.4561 0.0145 ***1.3586 1.0189 
Constant ***-3.0798 0.0263 ***391.4 1.0181 
Nr of observations 4,190,088 2,568,273 
  Log likelihood -16,255,102 
  AIC 12.6584 
*significant at the 90% level 
**significant at the 95% level 
***significant at the 99% level 
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Appendix – Condensed Ethnic groups 
Original Ethnic group Original 
code 
Condensed ethnic group 
European not further defined 10 
European New Zealand European  11 
Other European 12 
New Zealand Maori 21 
Maori 
Cook Island Maori 32 
Pacific Island not further defined 30 
Pacific Islands 
Samoan 31 
Tongan 33 
Niuean 34 
Tokelauan 45 
Fijian 36 
Other Pacific Island (not listed) 37 
Asian not further defined 40 
Asian 
South east Asian 41 
Chinese 42 
Indian 43 
Other Asian 44 
Middle Eastern 51 
Other 
Latin American/Hispanic 52 
African 53 
Other 54/61 
Not known/not stated 94/99 
Not stated/known Refuse to answer 95 
Response unidentifiable 97 
 
 
